Overview Dividends

(GH) Guardant Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099

Liquid Biopsy, Tumor Tissue Test, Genomic Cancer Assay, Companion Diagnostic Kit

GH EPS (Earnings per Share)

EPS Growth (3Y CAGR): 156.65%
EPS Trend (3Y Correlation): 83.8%

GH Revenue

Revenue Growth (3Y CAGR): 30.74%
Revenue Trend (3Y Correlation): 99.0%

Risk via 10d forecast
Volatility	63.4%
Value at Risk 5%th	90.5%

Reward
Sharpe Ratio	2.10
Alpha Jensen	219.35

Character
Hurst Exponent	0.638
Beta	1.535

Drawdowns 3y
Max DD	70.14%
Mean DD	37.48%

Description: GH Guardant Health November 05, 2025

Guardant Health, Inc. (NASDAQ:GH) is a precision-oncology firm that offers a portfolio of liquid-biopsy and tissue-based diagnostic assays, including Guardant360 (a 730-gene panel), Guardant360 CDx, Guardant360 Response, GuardantINFINITY, GuardantConnect, and GuardantOMNI, plus AI-enhanced PD-L1 detection and the Guardant Reveal Test for early-stage surveillance. The company also provides companion-diagnostic development services, regulatory support, and kit fulfillment for its Shield screening tests.

Key operational metrics as of Q3 2024 show annual revenue of roughly $720 million, a 38 % year-over-year increase driven primarily by expanding adoption of Guardant360 CDx in oncology clinical trials and rising reimbursement rates for liquid biopsies under Medicare’s new coverage policies. The firm’s gross margin has stabilized near 78 %, reflecting economies of scale in assay production and a shift toward higher-margin software solutions such as GuardantConnect.

Sector-wide, the liquid-biopsy market is projected to grow at a CAGR of 14 % through 2030, fueled by the broader shift toward personalized cancer therapy, the increasing prevalence of targeted drugs, and payer incentives for non-invasive monitoring. Guardant’s competitive moat is reinforced by its extensive real-world genomic database (>1 million patient profiles), which underpins its AI-driven analytics and positions the company to capture a larger share of companion-diagnostic contracts with major biopharma partners.

For a deeper quantitative assessment of Guardant Health’s valuation and risk profile, consider exploring the detailed analyst models on ValueRay.

GH Stock Overview

Market Cap in USD	11,647m
Sub-Industry	Health Care Services
IPO / Inception	2018-10-04
Return 12m vs S&P 500	188%
Analyst Rating	4.50 of 5

GH Dividends

Currently no dividends paid

GH Growth Ratios

CAGR	24.25%
CAGR/Max DD Calmar Ratio	0.35
CAGR/Mean DD Pain Ratio	0.65
Current Volume	1900.6k
Average Volume	2548.6k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-398.8m TTM) > 0 and > 6% of Revenue (6% = 54.2m TTM)

FCFTA -0.21 (>2.0%) and ΔFCFTA -2.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 65.59% (prev 148.7%; Δ -83.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.17 (>3.0%) and CFO -222.9m > Net Income -398.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (124.8m) change vs 12m ago 1.43% (target <= -2.0% for YES)

Gross Margin 63.76% (prev 81.07%; Δ -17.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 64.11% (prev 44.99%; Δ 19.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -90.01 (EBITDA TTM -370.9m / Interest Expense TTM 3.36m) >= 6 (WARN >= 3)

Altman Z'' -7.57

(A) 0.46 = (Total Current Assets 828.9m - Total Current Liabilities 236.9m) / Total Assets 1.28b

(B) -2.24 = Retained Earnings (Balance) -2.87b / Total Assets 1.28b

warn (B) unusual magnitude: -2.24 — check mapping/units

(D) -1.76 = Book Value of Equity -2.87b / Total Liabilities 1.63b

Total Rating: -7.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.55

1. Piotroski 1.50pt = -3.50

2. FCF Yield -2.12% = -1.06

3. FCF Margin -29.05% = -7.50

4. Debt/Equity -3.67 = -2.50

5. Debt/Ebitda -1.94 = -2.50

6. ROIC - WACC (= -44.45)% = -12.50

7. RoE 151.9% = 2.50

8. Rev. Trend 98.98% = 7.42

9. EPS Trend 83.75% = 4.19

What is the price of GH shares?

As of November 12, 2025, the stock is trading at USD 97.71 with a total of 1,900,647 shares traded.
Over the past week, the price has changed by -0.44%, over one month by +58.29%, over three months by +78.30% and over the past year by +232.80%.

Is Guardant Health a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Guardant Health (NASDAQ:GH) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 34.55 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GH is around 94.58 USD . This means that GH is currently overvalued and has a potential downside of -3.2%.

Is GH a buy, sell or hold?

Guardant Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy GH.

Strong Buy: 15
Buy: 6
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the GH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	86.4	-11.6%
Analysts Target Price	86.4	-11.6%
ValueRay Target Price	107.4	9.9%

GH Fundamental Data Overview November 01, 2025

Market Cap USD = 11.65b (11.65b USD * 1.0 USD.USD)
P/S = 14.0526
P/B = 55.6696
Beta = 1.535
Revenue TTM = 902.6m USD
EBIT TTM = -302.6m USD
EBITDA TTM = -370.9m USD
Long Term Debt = 1.14b USD (from longTermDebt, last fiscal year)
Short Term Debt = 58.4m USD (from shortTermDebt, last fiscal year)
Debt = 1.30b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 720.0m USD (from netDebt column, last quarter)
Enterprise Value = 12.37b USD (11.65b + Debt 1.30b - CCE 580.0m)
Interest Coverage Ratio = -90.01 (Ebit TTM -302.6m / Interest Expense TTM 3.36m)
FCF Yield = -2.12% (FCF TTM -262.2m / Enterprise Value 12.37b)
FCF Margin = -29.05% (FCF TTM -262.2m / Revenue TTM 902.6m)
Net Margin = -44.18% (Net Income TTM -398.8m / Revenue TTM 902.6m)
Gross Margin = 63.76% ((Revenue TTM 902.6m - Cost of Revenue TTM 327.1m) / Revenue TTM)
Gross Margin QoQ = 64.71% (prev 65.01%)
Tobins Q-Ratio = 9.69 (Enterprise Value 12.37b / Total Assets 1.28b)
Interest Expense / Debt = 0.07% (Interest Expense 943.0k / Debt 1.30b)
Taxrate = -0.15% (negative due to tax credits) (136.0k / -92.6m)
NOPAT = -303.0m (EBIT -302.6m * (1 - -0.15%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.50 (Total Current Assets 828.9m / Total Current Liabilities 236.9m)
Debt / Equity = -3.67 (negative equity) (Debt 1.30b / totalStockholderEquity, last quarter -354.5m)
Debt / EBITDA = -1.94 (negative EBITDA) (Net Debt 720.0m / EBITDA -370.9m)
Debt / FCF = -2.75 (negative FCF - burning cash) (Net Debt 720.0m / FCF TTM -262.2m)
Total Stockholder Equity = -262.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.23% (Net Income -398.8m / Total Assets 1.28b)
RoE = 151.9% (negative equity) (Net Income TTM -398.8m / Total Stockholder Equity -262.6m)
RoCE = -34.39% (EBIT -302.6m / Capital Employed (Equity -262.6m + L.T.Debt 1.14b))
RoIC = -33.94% (negative operating profit) (NOPAT -303.0m / Invested Capital 892.8m)
WACC = 10.51% (E(11.65b)/V(12.95b) * Re(11.67%) + D(1.30b)/V(12.95b) * Rd(0.07%) * (1-Tc(-0.00)))
Discount Rate = 11.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.62%
Fair Price DCF = unknown (Cash Flow -262.2m)
EPS Correlation: 83.75 | EPS CAGR: 156.7% | SUE: 1.98 | # QB: 3
Revenue Correlation: 98.98 | Revenue CAGR: 30.74% | SUE: 3.39 | # QB: 6

Additional Sources for GH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle